Heroes in Drug Discovery.

This award celebrates scientists who have made significant contributions to human healthcare.

The RISE Fellows at Drew University have selected Amgen’s drug discovery program of LUMAKRAS (sotorasib) as recipients of Drew University’s “Heroes in Drug Discovery” award based on the discovery of the first FDA approved KRAS inhibitor for the treatment of cancer.

Through the Heroes program, our objective is to celebrate individuals who have made significant contribution to healthcare, as well as connect them to the best and brightest science undergraduates whose passions, interests, and drive position them to be the next leaders in science research.

This event is supported by a grant from Pfizer and administered by the Independent College Fund of NJ.

Award Presentation
Wednesday, November 17th, 2021 • 7:00 pm
Online Zoom presentation

Zoom link for the event: https://drew.zoom.us/j/92521130257

Drew University’s Research Institute for Scientists Emeriti will honor Amgen’s drug discovery program of LUMAKRAS (sotorasib) as the recipients of the “Heroes in Drug Discovery Award” for the discovery of the first FDA approved KRAS inhibitor for the treatment of cancer. KRAS is one of the most frequently mutated oncogenes in human cancer. For three decades, research approaches targeting KRAS-mutant cancers have largely failed and KRAS was considered an
“undruggable” target. The Amgen team has succeeded in targeting a specific mutant, G12C, that is found in 14% of lung cancer patients using a first in class covalent inhibitor. Dr. Brian Lanman will present a one-hour seminar describing this outstanding research effort.

Links to event promotion flyers: for the event, for Dr. Lanman’s presentation

RSVP

To register/RSVP for this event, please use the form below. If you have any questions, please email rise@drew.edu.